Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a "Moderate Buy" consensus rating from eight analysts, with an average 12-month price target of $20.29. Despite beating recent earnings and revenue estimates, the company remains unprofitable. Institutional investors own nearly 95% of the stock, which is currently trading around $13.14.
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Enanta Pharmaceuticals announced that preclinical data from its STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI), held from April 15-19, 2026. The presentations will cover the preclinical tolerability, efficacy in blocking Th2 inflammation, discovery and characterization, and pharmacokinetic profile of their STAT6 inhibitor, EPS-3903, for allergic and autoimmune diseases. This highlights Enanta's ongoing efforts to develop small molecule drugs for immunological conditions.
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026
Enanta Pharmaceuticals, Inc. announced that it will present preclinical data from its STAT6 inhibitor program in four poster sessions at IMMUNOLOGY2026™, the annual meeting of the American Association of Immunologists (AAI). The presentations will highlight findings on the oral STAT6 inhibitor EPS-3903, focusing on its tolerability, efficacy in blocking Th2 inflammation in a mouse model, discovery and characterization, and pharmacokinetics for once-daily dosing in humans. These findings demonstrate the potential of EPS-3903 for treating allergic and autoimmune diseases.
Vanguard disaggregates holdings; reports 0 shares of Enanta (ENTA)
Vanguard Group has filed an amended Schedule 13G for Enanta Pharmaceuticals Inc. (ENTA), reporting 0 shares beneficially owned due to an internal realignment on January 12, 2026. This change means Vanguard's subsidiaries and business divisions will now report their beneficial ownership separately. The filing, dated March 26, 2026, and signed by Ashley Grim, Head of Global Fund Administration, indicates a neutral impact from this reporting change.
Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Analysts at Rodman & Renshaw
Rodman & Renshaw has initiated coverage on Enanta Pharmaceuticals (NASDAQ:ENTA) with a "buy" rating and a $20.00 price target, suggesting a significant upside. Despite beating quarterly earnings estimates, the company remains unprofitable with a negative net margin. The consensus among analysts is a "Moderate Buy," with institutional investors holding a substantial portion of the shares.
Federal Circuit schedules oral argument in Enanta’s patent case against Pfizer
The Federal Circuit has scheduled an oral argument for May 11, 2026, in the patent infringement case between Enanta Pharmaceuticals and Pfizer. Enanta is seeking damages from Pfizer, alleging infringement of a patent related to Pfizer's COVID-19 antiviral medication, Paxlovid. This development follows Enanta's appeal in February 2025, and the company has seen significant stock performance recently.
How Enanta Pharmaceuticals Inc. (ENTA) Affects Rotational Strategy Timing
This article analyzes Enanta Pharmaceuticals Inc. (ENTA) stock, noting weak near and mid-term sentiment despite a strong long-term outlook. It provides specific institutional trading strategies including position trading, momentum breakout, and risk hedging with defined entry, target, and stop-loss zones. The analysis also covers multi-timeframe signal strengths, support, and resistance levels for ENTA.
ENTA SEC Filings - Enanta Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Enanta Pharmaceuticals (ENTA) SEC filings, including annual 10-K, quarterly 10-Q, and material event 8-K forms, accessible through Stock Titan. It highlights key events such as patent litigation against Pfizer, financial results with royalty revenue and net losses, clinical trial updates for zelicapavir, and insider trading records. The platform offers AI-powered summaries to help investors understand the implications of complex documents for Enanta's virology and immunology pipelines.
Free cash flow per share of Enanta Pharmaceuticals, Inc. – FWB:9EP
This article provides financial information for Enanta Pharmaceuticals, Inc. (FWB:9EP), specifically focusing on its free cash flow per share. It appears to be a financial data page from TradingView, displaying historical values and changes in this metric, without providing a detailed analysis or narrative.
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
Enanta Pharmaceuticals presented its strategy at the Citizens Life Sciences Conference, outlining Phase 3 plans for its RSV drug zelicapavir, targeting high-risk adults. The company also highlighted its second RSV candidate, EDP-323, which showed rapid viral load reduction, and announced expansion of its oral immunology pipeline with several small-molecule programs for mast cell-driven diseases and atopic dermatitis. Enanta reported a strong cash position of $242 million, providing funding into fiscal 2029 for these initiatives.
Enanta (ENTA) director Lesley Russell receives stock options on 20,000 shares
Enanta Pharmaceuticals director Lesley Russell was granted stock options for 20,000 shares of common stock. The options have an exercise price of $14.17 per share and an expiration date of March 11, 2036. These options will vest in substantially equal monthly installments over one year, starting March 11, 2026, with the final installment vesting before the 2027 annual stockholders' meeting.
Commodore Capital LP Buys New Holdings in Enanta Pharmaceuticals, Inc. $ENTA
Commodore Capital LP acquired a new position of 800,000 shares in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) during the third quarter, valued at approximately $9.58 million, representing about 3.74% of the company. Despite reporting better-than-expected EPS and revenue, Enanta Pharmaceuticals remains unprofitable with negative margins. The stock currently trades around $12.70, holds a "Moderate Buy" consensus analyst rating, and has a target price of $20.33.
Enanta (ENTA) director receives grant of 20,000 options at $14.17
Enanta Pharmaceuticals director Mark G. Foletta has been granted 20,000 stock options with an exercise price of $14.17 per share, expiring on March 11, 2036. This grant, which vests monthly over one year starting March 11, 2026, is part of his routine equity-based director compensation. Following this transaction, Foletta directly holds options for 20,000 shares.
Enanta (ENTA) director awarded stock option for 20,000 shares
ENANTA PHARMACEUTICALS director Kristine Peterson was granted stock options for 20,000 shares of common stock. The options, granted on March 11, 2026, have an exercise price of $14.17 per share and expire on March 11, 2036. They will vest in substantially equal monthly installments over one year, reflecting a compensation award rather than a market transaction.
(ENTA) and the Role of Price-Sensitive Allocations
This article provides an analysis of Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) for March 14, 2026, highlighting a weak near-term sentiment but strong long-term outlook. It presents AI-generated trading strategies for different risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis. The report also details entry, target, and stop-loss levels based on predictive AI models.
Enanta (ENTA) awards 20,000 stock options to director Yujiro S. Hata
Enanta Pharmaceuticals (ENTA) director Yujiro S. Hata was granted 20,000 stock options with an exercise price of $14.17. The options were granted on March 11, 2026, and will vest in substantially equal monthly installments over one year, expiring on March 11, 2036. This transaction consolidates Hata's direct holdings to 20,000 stock options.
Enanta (NASDAQ: ENTA) director receives 20,000-share stock option grant
Enanta Pharmaceuticals director Terry Vance was granted stock options for 20,000 shares of common stock, with an exercise price of $14.17 per share and an expiration date of March 11, 2036. These options will vest monthly in equal installments over one year, starting March 11, 2026. This is a compensation-related grant rather than an open-market purchase, increasing his potential future equity exposure.
Enanta (NASDAQ: ENTA) awards director 20,000-share stock option grant
Enanta Pharmaceuticals (NASDAQ: ENTA) director Bruce L. A. Carter was granted stock options for 20,000 shares with an exercise price of $14.17 per share, expiring on March 11, 2036. The options will vest monthly over one year, starting March 11, 2026, with final vesting before the 2027 annual stockholders meeting. Following this grant, Carter directly holds options for 20,000 shares.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals (NASDAQ: ENTA) has received a consensus "Moderate Buy" rating from seven brokerages, with an average one-year price target of $20.33. Institutional investors own 94.99% of the company, with notable increases in holdings by firms like Invesco and Krensavage in Q4. Despite beating Q4 earnings and revenue estimates, the company remains unprofitable with a negative net margin.
Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference
Enanta Pharmaceuticals, Inc. announced that its management will participate in a fireside chat at The Citizens Life Sciences Conference on March 10, 2026, in Miami Beach, FL. A live webcast and subsequent replay of the event will be available on the "Events and Presentations" section of Enanta's website. Enanta is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases.
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Above 200-Day Moving Average - Here's Why
Enanta Pharmaceuticals (NASDAQ:ENTA) saw its share price move above its 200-day moving average, trading as high as $15.48 before settling at $13.74. Analysts have a consensus "Moderate Buy" rating with a target price of $20.33, despite the company remaining unprofitable with a negative ROE and net margin. Institutional investors have recently increased their holdings in ENTA.
Responsive Playbooks and the ENTA Inflection
The article analyzes Enanta Pharmaceuticals Inc. (NASDAQ: ENTA), highlighting strong sentiment across all horizons and an ongoing mid-channel oscillation pattern. It presents exceptional risk-reward scenarios for both short and long positions based on AI-generated signals. Three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—are outlined with specific entry, target, and stop-loss levels.
ENTA SEC Filings - Enanta Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Enanta Pharmaceuticals (ENTA) SEC filings, including 10-K, 10-Q, and 8-K forms, detailing financial results, material events, and insider trading. Recent filings cover interim financial leadership appointments, quarterly financial results with stable royalty revenue but continued operating losses, and an insider's forfeiture of shares for tax withholding. The platform also offers AI-powered summaries to help understand complex regulatory documents.
Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight | Intercept Pharma, Enanta Pharma, COUR Pharma, Novartis, Gannex Pharma, Nanjing Chia-tai Tianqing Pharm
The Primary Biliary Cholangitis (PBC) market is projected to reach approximately USD 1,150 million in 2023 and is expected to grow significantly by 2034, driven by innovation, increased disease awareness, and advancements in second-line therapies. Key companies like Intercept Pharma, Zydus Therapeutics, and Gilead Sciences are developing and launching new treatments for PBC, addressing unmet needs despite challenges like high therapy costs and safety concerns with some existing drugs. The report highlights historical and forecasted epidemiological trends across major markets, emphasizing the higher prevalence in women and those aged 40-70.
Primary Biliary Cholangitis Market: Rapid Increment Driven by Innovation by 2034 – DelveInsight
The report from DelveInsight indicates that the Primary Biliary Cholangitis (PBC) market is expected to experience rapid growth by 2034, driven by innovation, increasing disease awareness, and advancements in therapy. Key market players like Intercept Pharma, Zydus Therapeutics, and Gilead Sciences are developing and launching new treatments, with the market size estimated at USD 1,150 million in 2023. The report also highlights the epidemiological trends, showing a higher prevalence in women and individuals aged 40-70.
[EFFECT] ENANTA PHARMACEUTICALS INC SEC Filing
This article reports on an SEC filing by Enanta Pharmaceuticals Inc. (ENTA), specifically a Notice of Effectiveness for an S-3 form, which became effective on February 20, 2026, at 4:00 PM. The filing's impact and sentiment are classified as neutral. The article also provides recent news and SEC filing activities for Enanta Pharmaceuticals, along with key stock data.
ENTA Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Enanta Pharmaceuticals Inc (ENTA), including its income statement, balance sheet, cash flow, and key financial ratios. It highlights the company's profitability, growth, leverage, liquidity, and cash flow, revealing a weak overall financial health score of 24/100 based on FY2025 annual data. Key financial metrics such as revenue, EBITDA, free cash flow, net income, and EPS are presented with year-over-year changes and CAGR.
Understanding the Setup: (ENTA) and Scalable Risk
This article provides an in-depth analysis of Enanta Pharmaceuticals Inc. (ENTA), highlighting a weak near-term sentiment but strong mid and long-term outlooks. It details institutional trading strategies, including long, momentum breakout, and short positions, along with AI-generated signals and risk management parameters. The analysis focuses on resistance and support levels, offering specific entry, target, and stop-loss prices for different trading approaches.
Enanta Pharmaceuticals (ENTA) Quarterly Loss Narrows Yet Keeps Profitability Concerns In Investor Focus
Enanta Pharmaceuticals (ENTA) reported a Q1 2026 revenue of US$18.6 million and an EPS loss of US$0.42, with a net income loss of US$11.9 million, indicating continued unprofitability despite narrowing losses on a trailing 12-month basis. Analysts emphasize revenue growth as the main upside, but persistent losses and a lower-than-average price-to-sales ratio, coupled with shareholder dilution and insider selling, raise concerns about the company's path to profitability.
The Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Enanta Pharmaceuticals (NASDAQ:ENTA) exceeded analyst expectations in its first-quarter results, with revenues of US$19m surpassing forecasts by 22% and statutory losses significantly smaller than predicted. Despite these strong results, analysts have not significantly changed their revenue estimates for 2026, though loss per share forecasts have seen a promising decrease. The consensus price target remains at US$19.25, indicating that the improved loss estimates have not yet translated into a long-term positive impact on stock valuation, and the company still faces a forecast revenue decline worse than the industry average.
Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results
Enanta Pharmaceuticals (NASDAQ: ENTA) exceeded revenue expectations in its first quarter, reporting US$19 million, and significantly reduced its statutory loss per share to US$0.42. Analysts have updated their estimates, maintaining a revenue forecast of US$65.3 million for 2026, but notably decreasing the projected loss per share to US$2.35, indicating improved sentiment. Despite the positive adjustments, the company is still expected to experience revenue decline, performing worse than the wider biotech industry.
Enanta Pharma (ENTA): Analyst Reiterates Buy Rating with $20 PT
HC Wainwright & Co. has reiterated a Buy rating on Enanta Pharma (ENTA) with a price target of $20, maintaining a steady outlook. This decision comes despite varied analyst actions in recent months, highlighting consistent confidence in the biotechnology company's future performance. Analysts' average target price for ENTA is $19.13, suggesting a potential upside of 37.99% from its current price.
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for
Enanta Pharmaceuticals will present preclinical data for EDP-978, their KIT inhibitor for mast cell-mediated, Type 2 immune diseases, at the 2026 AAAAI Annual Meeting. The presentations will cover the discovery of the potent and selective inhibitor and its pharmacokinetic profile with potential for once-daily dosing. These findings will be shared in two poster sessions on February 27, 2026.
Enanta Pharma (ENTA): Analyst Reiterates Buy Rating with $20 PT | ENTA Stock News
HC Wainwright & Co. has reiterated a Buy rating for Enanta Pharma (ENTA), maintaining a price target of $20, signaling stable confidence in the company's future. This rating aligns with the average target price of $19.13 from 8 analysts, suggesting a 37.99% upside from the current price. Enanta Pharma is a biotechnology company focused on developing small-molecule candidates for virology and immunology applications.
HC Wainwright Reaffirms "Buy" Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)
HC Wainwright has reaffirmed its "Buy" rating for Enanta Pharmaceuticals (NASDAQ:ENTA), setting a price target of $20.00, which suggests a 44.6% upside. This comes after the biotechnology company reported better-than-expected earnings and revenue for the quarter. The consensus among analysts is a "Moderate Buy" with an average price target of $20.33.
Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting
Enanta Pharmaceuticals will present preclinical data for its KIT inhibitor, EDP-978, at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The data will be showcased in two poster presentations focusing on EDP-978's discovery as a potent and selective KIT inhibitor for mast cell-mediated diseases, and its favorable pharmacokinetic profile suggesting once-daily dosing potential. EDP-978 is in development for the treatment of Type 2 immune diseases.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Enanta Pharmaceuticals reported financial results for its fiscal first quarter ended December 31, 2025, showing total revenue of $18.6 million and a net loss of $11.9 million. The company is advancing its RSV treatment pipeline, including zelicapavir, and expanding its immunology programs with new candidates targeting MRGPRX2, KIT, and STAT6 inhibitors. Enanta maintains a strong financial position with $241.9 million, projecting a cash runway into fiscal 2029.
Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates
Enanta Pharmaceuticals (ENTA) reported a Q1 loss of $0.42 per share, exceeding the Zacks Consensus Estimate of a $0.54 loss and showing improvement from a $1.05 loss a year ago. The biotechnology company also surpassed revenue estimates, posting $18.62 million against an expected $15.58 million. Despite these positive earnings surprises, Enanta Pharmaceuticals' shares have declined by 14.3% year-to-date, underperforming the S&P 500.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025
Enanta Pharmaceuticals, a clinical-stage biotechnology company, announced its financial results for the fiscal first quarter ended December 31, 2025, reporting a total revenue of $18.6 million primarily from MAVYRET/MAVIRET royalties. The company highlighted significant progress in its RSV treatment portfolio, with zelicapavir advancing towards a Phase 3 study, and expanded its immunology pipeline with a new program targeting MRGPRX2 inhibitors. Despite a net loss of $11.9 million, Enanta anticipates its current cash and future royalty revenue will fund operations and development programs into fiscal year 2029.
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 202
Enanta Pharmaceuticals reported its financial results for the fiscal first quarter ended December 31, 2025, showing total revenue of $18.6 million and a net loss of $11.9 million. The company highlighted significant progress in its RSV treatment portfolio, including preparing zelicapavir for Phase 3 studies, and expanded its immunology pipeline with new programs targeting MRGPRX2, KIT, and STAT6 inhibitors. Enanta maintains a strong financial position of $241.9 million, anticipating a cash runway into fiscal 2029.
Enanta Pharmaceuticals (NASDAQ:ENTA) Posts Earnings Results, Beats Estimates By $0.12 EPS
Enanta Pharmaceuticals (NASDAQ:ENTA) reported earnings results, beating analyst estimates with an EPS of -$0.42 against a consensus of -$0.54 and revenue of $18.62M exceeding expectations. Despite a 2.4% stock increase to $13.83, the company remains unprofitable with negative ROE and net margin, and analysts hold a "Moderate Buy" rating with an average target price of $20.33. Insider selling of over 11,000 shares was noted, while institutional investors hold approximately 95% of the stock.
Enanta Pharmaceuticals: Overview of Fiscal First Quarter Earnings
Enanta Pharmaceuticals Inc. reported a net loss of $11.9 million, or 42 cents per share, for its fiscal first quarter. The biotechnology firm's revenue for the quarter reached $18.6 million. This financial report was produced by Automated Insights using data from Zacks Investment Research.
Enanta Pharmaceuticals: Overview of Fiscal First Quarter Earnings
Enanta Pharmaceuticals Inc. reported a net loss of $11.9 million, or 42 cents per share, for its fiscal first quarter. The biotechnology firm recorded $18.6 million in revenue during this period. The article was produced by Automated Insights using data from Zacks Investment Research.
Enanta Pharmaceuticals (NASDAQ: ENTA) cuts loss while advancing RSV and immunology pipeline
Enanta Pharmaceuticals reported a significantly narrower net loss of $11.9 million for its fiscal first quarter ended December 31, 2025, compared to $22.3 million in the prior year, driven by increased revenue from MAVYRET®/MAVIRET® royalties and reduced operating expenses. The company maintains a strong financial position with $241.9 million in cash, projecting a cash runway into fiscal 2029, and is actively advancing its RSV pipeline, including Phase 3 enabling work for zelicapavir, and several immunology programs, like KIT inhibitor EDP-978 and STAT6 inhibitor EPS-3903. Key milestones for 2026 include planned IND filings and data readouts for its immunology candidates.
The Technical Signals Behind (ENTA) That Institutions Follow
This article analyzes Enanta Pharmaceuticals Inc. (NASDAQ: ENTA) using AI models to identify institutional trading signals. It highlights strong near-term sentiment, potential support and resistance levels, and an exceptional risk-reward setup targeting an 18.8% gain. Three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—are presented for varying risk profiles.
Earnings Preview For Enanta Pharma
Enanta Pharma (NASDAQ: ENTA) is set to release its quarterly earnings on February 9, 2026, with analysts expecting an EPS of $-0.74. The company's stock has seen a 174.08% increase over the last 52 weeks, and analysts have a "Buy" consensus rating with an average one-year price target of $18.5. Despite strong revenue growth, Enanta Pharma faces challenges with its net margin, return on equity, and debt-to-equity ratio compared to peers.
Enanta Pharmaceuticals (ENTA) Projected to Post Quarterly Earnings on Monday
Enanta Pharmaceuticals (ENTA) is slated to announce its Q1 2026 earnings on Monday, February 9th, with analysts forecasting a loss of ($0.54) per share and revenue of $16.14 million. The company's stock currently trades around $12.90, and despite a "Moderate Buy" consensus rating from analysts with an average price target of $20.33, insiders have recently sold shares. Institutional ownership remains very high at approximately 95%.
Precision Trading with Enanta Pharmaceuticals Inc. (ENTA) Risk Zones
This article analyzes Enanta Pharmaceuticals Inc. (ENTA) focusing on risk zones and trading strategies. It highlights a potential negative sentiment in the mid-term despite long-term strength, identifying a significant risk-reward short setup. The analysis provides specific institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for near, mid, and long-term perspectives.
Enanta (NASDAQ: ENTA) seeks 1.6M-share boost to 2019 equity plan
Enanta Pharmaceuticals is asking stockholders to approve an amendment to its 2019 Equity Incentive Plan to add 1,600,000 shares, representing 5.5% of common shares outstanding, at its virtual annual meeting on March 11, 2026. The company states that this increase is crucial for attracting and retaining talent through equity awards, which are a central component of its compensation program. Stockholders will also vote on the election of two Class I directors, executive compensation on an advisory basis, and the ratification of PricewaterhouseCoopers LLP as the independent auditor.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals (NASDAQ:ENTA) has received a consensus "Moderate Buy" rating from seven research firms, with an average 12-month price target of $20.33, significantly higher than its recent open of $12.61. Despite reporting mixed quarterly results with continued unprofitability, analysts expect an EPS of -$4.65 for the current year. Insider selling by CEO Jay Luly and other executives, totaling $170,149 in the last 90 days, contrasts with substantial institutional ownership of nearly 95%.
